{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:07:36Z","timestamp":1787162856188,"version":"build-2736575974"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jval.2025.03.010","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T02:57:42Z","timestamp":1744340262000},"page":"1009-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States"],"prefix":"10.1016","volume":"28","author":[{"given":"Tanvi V.","family":"Chiddarwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawre","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Alarid-Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Garibay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna Roy","family":"Chowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce L.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Kuntz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2025.03.010_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.jval.2025.03.010_bib2","first-page":"240","article-title":"Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis","volume":"27","author":"Hepp","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jval.2025.03.010_bib4","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/CU9.0000000000000204","article-title":"Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: a narrative review","volume":"17","author":"Bantounou","year":"2023","journal-title":"Curr Urol"},{"issue":"10","key":"10.1016\/j.jval.2025.03.010_bib5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jval.2025.03.010_bib6","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.21468","article-title":"Evaluation of trends in oncology drug spending in Medicare, 2016 to 2020","volume":"5","author":"Kyle","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.jval.2025.03.010_bib7","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50 000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2025.03.010_bib8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.18553\/jmcp.2023.29.3.257","article-title":"Examining US commercial health plans\u2019 use of the Institute for Clinical and Economic Review\u2019s reports in specialty drug coverage decisions","volume":"29","author":"Chambers","year":"2023","journal-title":"JMCP"},{"issue":"10","key":"10.1016\/j.jval.2025.03.010_bib9","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jval.2025.03.010_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12916-021-02204-0","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"20","author":"Husereau","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.jval.2025.03.010_bib11","author":"Arias"},{"issue":"9","key":"10.1016\/j.jval.2025.03.010_bib13","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.jaip.2020.06.028","article-title":"Balancing cancer immunotherapy efficacy and toxicity","volume":"8","author":"Johnson","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.jval.2025.03.010_bib15","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2018.09.009","article-title":"Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy","volume":"2","author":"Patterson","year":"2019","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.jval.2025.03.010_bib16","article-title":"Healthcare costs associated with first-line (1L) treatment of patients with locally advanced or metastatic urothelial carcinoma (la\/mUC) in the United States (US)","volume":"19","author":"Ike","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"1","key":"10.1016\/j.jval.2025.03.010_bib19","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.clgc.2020.07.006","article-title":"Cost-effectiveness of Pembrolizumab versus carboplatin-based Chemotherapy as First-line Treatment of PD-L1\u2013positive Locally Advanced or Metastatic urothelial Carcinoma Ineligible for Cisplatin-based Therapy in the United States","volume":"19","author":"Hale","year":"2021","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.jval.2025.03.010_bib20","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"JCO"},{"key":"10.1016\/j.jval.2025.03.010_bib24","author":"Cubanski"},{"issue":"6","key":"10.1016\/j.jval.2025.03.010_bib25","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamaoncol.2016.4865","article-title":"Out-of-pocket spending and financial burden among Medicare beneficiaries with cancer","volume":"3","author":"Narang","year":"2017","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.jval.2025.03.010_bib26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMe2400311","article-title":"Enfortumab vedotin and pembrolizumab\u2014a new perspective on urothelial cancer","volume":"390","author":"G\u00fcnter","year":"2024","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2025.03.010_bib27","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.6004\/jnccn.2013.0176","article-title":"Determining chemotherapy tolerance in older patients with cancer","volume":"11","author":"Kim","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"10.1016\/j.jval.2025.03.010_bib28","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncy.22788","article-title":"Generic cancer drugs are still in short supply","volume":"132","author":"Nelson","year":"2024","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"10.1016\/j.jval.2025.03.010_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40273-023-01273-8","article-title":"Cost-effectiveness and economic impact of bladder cancer management: an updated review of the literature","volume":"41","author":"Joyce","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.jval.2025.03.010_bib30","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1007\/s12325-021-01950-0","article-title":"Cost-effectiveness of avelumab maintenance therapy for advanced or metastatic urothelial carcinoma in the United States","volume":"38","author":"Peng","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.jval.2025.03.010_bib31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.eururo.2018.03.006","article-title":"Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer","volume":"74","author":"Sarfaty","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.jval.2025.03.010_bib32","doi-asserted-by":"crossref","first-page":"180.e11","DOI":"10.1016\/j.urolonc.2018.11.016","article-title":"Effect of PD-L1 testing on the cost-effectiveness and budget impact of pembrolizumab for advanced urothelial carcinoma of the bladder in the United States","volume":"37","author":"Criss","year":"2019","journal-title":"Urol Oncol"},{"key":"10.1016\/j.jval.2025.03.010_bib33","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211068733","article-title":"Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"14","author":"Wu","year":"2022","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"10.1016\/j.jval.2025.03.010_bib34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jval.2025.03.010_bib36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine\u2013cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden Michiel","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jval.2025.03.010_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.1215","article-title":"Significance of PD-L1 in metastatic urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"7","author":"Maiorano","year":"2024","journal-title":"JAMA Netw Open"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525019667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525019667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:53:16Z","timestamp":1782964396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525019667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1098301525019667"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}